Product Description
Mechanisms of Action: DR Antagonist,ADR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bulgaria | Czech | Denmark | Estonia | Finland | Hungary | Iceland | India | Ireland | Italy | Korea | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Russia | Saudi Arabia | Slovakia | Sweden | Switzerland | Taiwan | Ukraine | United Kingdom | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: University Medical Center Groningen
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BAR-MEDS Chlorprothixene | N/A |
Recruiting |
Obesity, Morbid |
2026-12-01 |
|
Q10-12 | N/A |
Completed |
Schizophrenia|Psychotic Disorders|Type 2 Diabetes|Affective Disorders, Psychotic|Bipolar Disorder |
2012-12-01 |